Overview
ACM Global Laboratories provides laboratory testing and diagnostic services for clinical trials, toxicology, and patient care. It runs a global network of wholly-owned and partner labs in over 65 countries and conducts more than 30 million tests each year. Its core offerings include customized central lab services (sample logistics and data management), bioanalytical services (drug development assays and validation), and toxicology, plus the DRUGSCAN brand for medication monitoring. The company grows by forming research partnerships with pharmaceutical and biotech clients, leveraging its long history (since 1975), Rochester Regional Health affiliation, and acquisitions to expand capabilities and reach its goal of delivering reliable laboratory data to support global clinical research.
Work here?Claim your company
Simplify's take
What believers are saying
- ACM's 2025 radiopharmaceutical launch targets a fast-growing oncology trial segment.
- The 2025 AGM and knowledge-center push signals active business development and thought leadership.
- Rochester Regional Health's Helix partnership expands genomics access and sponsor-facing credibility.
What critics are saying
- Thermo Fisher, Labcorp, and IQVIA pressure ACM's margins through larger global contracts.
- Radiopharmaceutical specialization needs heavy capital; slow adoption leaves ACM underutilized by 2027.
- A major quality failure in trial testing would poison sponsor trust and cripple repeat business.
What makes ACM Global Laboratories unique
- ACM serves clinical trials in 65 countries with wholly owned labs and partner network.
- ACM launched radiopharmaceutical lab services in 2025, expanding beyond standard central lab work.
- Rochester Regional Health ownership gives ACM healthcare credibility and deep operational resources.
Help us improve and share your feedback! Did you find this helpful?